Table 1 Assessment of the importance of the defined outcomes
Outcomes of interest for the first question | R1 | R2 | R3 | R4 | R5 | Importance |
|---|---|---|---|---|---|---|
1. Clinical remission one month after treatment | 8 | 9 | 9 | 9 | 8 | CRITICAL |
2. Endoscopic remission one month after treatment | 6 | 8 | 7 | 8 | 7 | CRITICAL |
3. Percentage of patients with mild adverse effects | 8 | 6 | 7 | 6 | 5 | IMPORTANT |
4. Percentage of patients with moderate-to-severe adverse effects | 9 | 8 | 9 | 8 | 8 | CRITICAL |
5. Clinical remission 12 months after treatment | 7 | 6 | 8 | 6 | 8 | IMPORTANT# |
Outcomes of interest for the second question | R1 | R2 | R3 | R4 | R5 | Importance |
1. Percentage of patients who don't require corticosteroids one month after treatment | 8 | 9 | 8 | 8 | 8 | CRITICAL |
2. Mean Reduction of Corticosteroids dose one month after treatment | 9 | 6 | 7 | 6 | 6 | IMPORTANT |
3. Clinical remission one month after treatment (no corticosteroids) | 8 | 8 | 7 | 8 | 8 | CRITICAL |
4. Endoscopic remission one month after treatment (no corticosteroids) | 7 | 8 | 6 | 6 | 8 | IMPORTANT# |
5. Improvement of Quality of life (Inflammatory Bowel Disease Questionnaire, or IBDQ) | 7 | 8 | 8 | 6 | 9 | CRITICAL |
6. Colectomy rate during the follow-up | 9 | 9 | 9 | 8 | 9 | CRITICAL |
7. Percentage of patients with long-term adverse effects | 9 | 8 | 8 | 8 | 9 | CRITICAL |
8. Clinical remission 12 months after treatment | 7 | 6 | 7 | 7 | 8 | CRITICAL |